Nathaniel Marchetti, DO
Enriched profileProfessor of Thoracic Medicine and Surgery; Vice Chair for Clinical Affairs, Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University; Medical Director, Respiratory Intensive Care Unit, Temple University Hospital · Lewis Katz School of Medicine at Temple University
Nathaniel Marchetti is Professor of Thoracic Medicine and Surgery; Vice Chair for Clinical Affairs, Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University; Medical Director, Respiratory Intensive Care Unit, Temple University Hospital at Lewis Katz School of Medicine at Temple University. OpenAlex indexes 254 publications with 6,851 citations (h-index 36); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Nathaniel Marchetti, DO, is Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University / Temple University Hospital (Temple Lung Center). The public record shows 254 publications with 6,851 citations (h-index 36), centered on COPD. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 9 companies, 2 NIH-funded awards (2018–2024).
- Most recent indexed publication: 2026 · Pulmonary circulation
- Top research focus: COPD
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 3 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Sponsor: Johns Hopkins University
- Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Sponsor: Apreo Health, Inc.
- Biological Effects of Quercetin in COPD Phase II
Sponsor: Temple University
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Chiesi USA, Inc.Program year20252 payments
- CSL BehringProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
23.2%Short-acting sulfonamides7.8%Sulfamethoxazole-Trimethoprim100%Part D≥63 patientsMacrolide Antimicrobial7.6%Azithromycin100%Part D≥76 patientsRespiratory
22.3%Corticosteroid10.9%Trelegy Ellipta36%Breztri Aerosphere22%Symbicort12%Fluticasone Propionate11%Breo Ellipta10%Budesonide-Formoterol Fumarate7%Dulera3%Part D<11 patientsbeta2-Adrenergic Agonist8.3%Albuterol Sulfate Hfa87%Ventolin Hfa10%Airsupra3%Part D<11 patientsMetabolism & gastrointestinal
21.4%Corticosteroid11.2%Prednisone100%Part D≥145 patientsProton pump inhibitor7%Pantoprazole Sodium93%Omeprazole7%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2018–2024 per NIH RePORTER. The latest:
- Impact of quercetin on inflammatory and oxidative stress markers in COPD
Temple Univ of the Commonwealth
FY2024$371,479R33AT009991 - Impact of quercetin on inflammatory and oxidative stress markers in COPD
Temple Univ of the Commonwealth
FY2023$375,403R33AT009991 - Impact of quercetin on inflammatory and oxidative stress markers in COPD
Temple Univ of the Commonwealth
FY2022$386,229R33AT009991
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Anabolic Medications for Muscle Wasting in Chronic Obstructive Pulmonary Disease. Is the Evidence Getting Stronger?
American journal of respiratory and critical care medicine
Comment2019
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/nathaniel-marchetti-do-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
hcplive.com/authors/nathaniel-marchetti-do
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗ - Other
lung.org/research/airways-clinical-research-centers/investigators/nathaniel-marchetti
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lung.org ↗ - Other
templehealth.org/about/news/in-the-media/dr-nathaniel-marchetti-offers-commentary-to-medscape-on-new-study-testing-wearable-tech-for-copd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- DO
Philadelphia College of Osteopathic Medicine, Philadelphia, PA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗ - American Board of Internal Medicine - Board Certified
Pulmonary Disease
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗ - American Board of Internal Medicine - Board Certified
Critical Care Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
- First Place
Annual Sol Sherry Resident and Fellow Research Conference
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
Secondary affiliations
appointments beyond the home institution- Principal Investigator
American Lung Association Airways Clinical Research Centers (ACRC) network
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lung.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →templehealth.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm